Abstract
Tumors contain a vastly complicated cellular network that relies on local communication to execute malignant programs. The molecular cues that are involved in cell-cell adhesion orchestrate large-scale tumor behaviors such as proliferation and invasion. We have recently begun to appreciate that many tumors contain a high degree of cellular heterogeneity and are organized in a cellular hierarchy, with a cancer stem cell (CSC) population identified at the apex in multiple cancer types. CSCs reside in unique microenvironments or niches that are responsible for directing their behavior through cellular interactions between CSCs and stromal cells, generating a malignant social network. Identifying cell-cell adhesion mechanisms in this network has implications for the basic understanding of tumorigenesis and the development of more effective therapies. In this review, we will discuss our current understanding of cell-cell adhesion mechanisms used by CSCs and how these local interactions have global consequences for tumor biology.
Keywords: cancer stem cell, cell adhesion, cell-cell communication
Introduction: Building the Network Infrastructure
Current treatment regimens for many solid tumors are still palliative in nature, usually involving a combination of surgical resection, aggressive radiation and chemotherapy. These treatments, despite significant initial regression of the tumor bulk, are often followed by tumor recurrence, decreased quality of life and eventually death. Malignant tumors of numerous origins are now recognized as a heterogeneous population of cells constituting a cellular hierarchy1 with therapeutically resistant stem-like cells, termed cancer stem cells (CSCs), at the summit.2 It should be noted that multiple models for tumor formation exist nonexclusively. Tumorigenesis may be explained by clonal evolution, microenvironmental factors and stem cell initiation.3 As such, one or a combination of these processes may be involved in individual tumor formation.
CSCs (also referred to as stem-like tumor cells, tumor initiating cells or tumor propagating cells) possess several features of normal stem cells, namely the ability to self-renew and recapitulate cell types of the specific organ, in this instance the diverse tumor mass. The defining feature of a CSC is its ability to form a tumor upon secondary transplantation. Using this functional assay, CSCs have been isolated from primary human cancers, including brain,4-8 breast,9 skin,10,11 colon12,13 and prostate.14 Mechanistic studies have been aimed at understanding the signaling pathways of CSCs, as this is critical for understanding their biology and will aid in the development of more potent therapeutic strategies.15 Complementary studies have been conducted with in vivo models and utilized microenvironments of different molecular backgrounds,16 highlighting the importance of direct and dynamic interaction of CSCs with the surrounding stromal microenvironment or “niche.”17 The complex niche interactions by CSCs regulate malignant programs. However, limited information is available as to how these aberrant cell populations home to and communicate with the microenvironment. Targeting the stem cell niche may permit control of CSC genesis and maintenance through cell-cell, cell-extracellular matrix and cell-soluble factor interactions.
The focus of this review will be to highlight adhesion and communication mechanisms involved in niche interactions. The contribution of many of these interactions are yet to be defined across CSC systems, but evidence demonstrates that they can impact the CSC phenotype in certain contexts. Cell-cell communication is likely to be involved in larger scale tumorigenic programs such as self-renewal,1 proliferation, survival, invasion18 and in some cases, epithelial to mesenchymal transition (EMT).19 The major interactions to be covered include tight junctions, gap junctions, integrins, cadherins and immunoglobulin superfamily cell adhesion molecules (CAMs) including junctional adhesion molecules (JAMs), receptor tyrosine phosphatase PTPμ, intercellular CAM (ICAM), L1CAM (CD171) and neural CAM (NCAM). The role of these communication and adhesion mechanisms are discussed in detail below and summarized in Figure 1. Importantly, little is known about how these structures modulate important cell fate decisions in CSCs. Determination of cell-cell interaction effects on symmetric and asymmetric division programs and EMT is likely to be informative considering the processes are vital to CSC compartment maintenance, outgrowth, and tumorigenic progression.
Figure 1. Cancer stem cell adhesion and communication mechanisms in the tumor microenvironment. Schematic summarizing cell adhesion and communication mechanisms between cell types in the tumor microenvironment and their role in CSC phenotypes.
Extracellular Matrix
The extracellular matrix (ECM) is a key component of many tumor microenvironments, allowing communication that can modify both the tumor cell and microenvironment, thereby promoting malignant phenotypes.20 Importantly, many tumor microenvironments, such as those in the brain, have a specialized ECM that is unique from normal ECM which mediates invasion.21,22 In addition to binding numerous receptors, integrins act as receptors for many ECM ligands (including laminins, fibronectin, collagens and vitronectin) and serve as signal transduction machinery, linking extracellular adhesion to intracellular programs. Integrins are known to interact with multiple receptors including EGFR,23 insulin like growth factor receptor (IGFR-1), platelet derived growth factor (PDGF),24 vascular endothelial growth factor receptor 2 (VEGF2)25 and the endothelial cell receptor Tie2.26 As such, they influence diverse signaling cascades such as PI3K and MEK-ERK27 and numerous cell types including endothelial cells and immune cells.
Cell Adhesion Molecules
CAMS are comprised by multiple groups including calcium-dependent integrins and cadherins and calcium-independent immunoglobulin superfamily cell adhesion molecules, which include JAM, PTPμ, NCAM, ICAM and L1CAM.28-30 These adhesion molecules have diverse functions in normal setting and have been shown to influence numerous immune cell types (monocytes, T cells, platelets and DC cells) as well as other stromal cells including fibroblasts and endothelial cells.28,31
Cadherins comprise a multi-member glycoprotein family of transmembrane calcium-dependent adhesion molecules that maintain tissue structure in normal and pathologic settings. This is accomplished through regulation of cell-cell interaction, migration and signaling.32 The cadherin super-family is defined by extracellular cadherin repeats, a central transmembrane region and variable intracellular binding domains conserved among each of the four subgroups, classical, desmosomal, atypical and protocadherin.33 The cadherins possess intrinsic signaling capabilities, modulating additional pathways depending on binding partners. These binding partners consist of varied extracellular receptors: these include fibroblast growth factor receptor 1 (FGFR1),34 epidermal growth factor receptor (EGFR)35 and Frizzled receptors.36 As such, cadherin family members have been shown to regulate diverse signaling pathways known to influence cell fate decisions including the MEK-ERK,37 canonical Wnt,38 FGF,34 AKT and PI3K signaling cascades.39 Additional partners include ADAM metaloproteases,40 integrins41 and cis and trans self-interaction,42 which directly regulate cell-cell interaction and migration. As such, cadherins are involved in the regulation of microenvironmental members including fibroblasts, endothelial cells and immune cells including T cells and macrophages.
JAMs are transmembrane adhesive glycoproteins that functionally participate in the organization of endothelial tight junctions (TJ) and mediate a variety of biological processes including leukocyte transendothelial migration.43,44 The JAM family consists of JAM-A, JAM-B and JAM-C, which are structurally composed of two immunoglobulin (Ig) extracellular loop domains and intracellular PDZ binding domains.45 Two JAM-A proteins can not only form dimers on the same cell but also between adjacent cells.46-50 This dimerization consequently activates the PDZ binding motif for interaction with other PDZ domain-containing proteins such as afadin and ZO-1.51,52 Additionally, it has been reported that the formation of afadin and PDZ-GEF2 complex in epithelial cells activates downstream Rap1A, which further stabilizes the protein level of integrin β1, a key CSC integrin.53
Protein tyrosine phosphorylation is a key process in cellular signaling with finite control accomplished through antagonistic actions of kinases and phosphatases which exist as soluble cytosolic and transmembrane proteins. Receptor tyrosine phosphatase PTPμ is a member of the meprin/A5/PTPμ (MAM) containing subclass of protein tyrosine phosphatases which regulates adhesion dependent signaling. PTPμ is comprised of an extracellular, juxtamembrane and two intracellular phosphatase domains.54 PTPμ stabilizes cell-cell contacts through homophilic interaction via its extracellular immunoglobulin domain54 as well as by interaction with E, N, and R55 and VE cadherin,56 β and γ catenin57 and gap junction protein Cx43.58
Neural cell adhesion molecule (NCAM) alternatively known as CD56 exists as three main isoform classes based on molecular weight; 120, 140 and 180 kDa. The 140 and 180 kDa isoforms are observed mainly in embryonic development with NCAM 120 present in adult tissues including neurons, glia, natural killer cells, T cells, skeletal muscle and the epithelia of multiple organs. NCAM possess conserved intracellular domains, a short transmembrane domain, and a large extracellular region consisting of repeated immunoglobulin and fibronectin III domains. Effects on cell-cell adhesion are mediated through homophilic binding, both cis and trans, via its immunoglobulin domain.59 Additional interaction with fibroblast growth factor receptor,60 N cadherin61 and β catenin62 has been observed indicating signaling potential. Additional studies have shown NCAM interaction with FGFRs influences β integrin expression,63 suggesting a role in the regulation of cell-matrix interactions.
ICAM-1 is a member of the intercellular cell adhesion molecule family consisting of five members, 1–5, which possess an extracellular domain with immunoglobulin repeats, a transmembrane domain, and cytoplasmic domain.64 Cell bound and soluble forms have been characterized: sICAM-1 is a product of proteolytic cleavage of the extracellular domain of cell membrane integrated ICAM-1.65 ICAM-1 expression has been observed on the macrophages,66 vascular endothelium, and lymphocytes67 and is associated with immune recognition of exposed endothelium as well as cellular extravasation. ICAM-1 is known to bind β integrins,68 Muc169 and fibrinogen,70 thereby modulating cell-cell and cell matrix interactions.
L1CAM (CD171) is expressed by leukocytes, epithelia of the intestine, neurons and Schwann cells, among other cell types, and is involved in embryogenesis, neuronal growth and extension and axonal outgrowth.71 L1CAM binds in a trans and cis homophilic manner72 as well as heterotypically with ECM proteins: these include chondroitin sulfate proteoglycan73 and integrin family members,74 thereby implicating this protein in cell-cell and cell-matrix interactions. Interestingly, L1CAM has also been shown to interact with NUMB,75 a protein known to regulate asymmetric cell division.
Tight junctions mediate cell-cell interactions in areas where the membranes of two closely associated cells join. In these areas of contact, networks are formed by rows of transmembrane proteins including main constituent claudin, occludins, E cadherin, JAMs, catenins and actin. Through these junctions, cytoskeletons of neighboring cells are fused together allowing efficient cell-cell interaction and communication.76 Tight junctions serve the two main functions of barrier formation and cell polarity control. The barriers formed by tight junctions may be of two types, functional or protective, and may be tight or leaky depending on the number of contacts. These differences permit tight junction fine tuning to mediate selective transport of ions and osmosis or complete blockade as observed in the protective barrier of the skin. Another important function of tight junctions is to dictate cell polarity through the prevention of lateral diffusion of integral membrane proteins. Tight junctions are therefore critically involved in epithelial to mesenchymal transition, a key aspect of the regulation of cell-cell contact and migration.77
With regards to cancer, CAMs impart varying effects on tumor growth, metastasis and outcome with effects showing tumor type specific differences.78,79 If generalizing, CAMs appear to function by and large as tumor supressors. Current knowledge regarding CAMs in CSCs is still relatively immature and conflicting, with a more detailed description of what has been characterized below.
Integrin Regulation in the CSC Microenvironment: Enabling Identification and ECM Communication
In the context of CSCs, integrins are also a critical component as they are active in specialized CSC niches. The role of integrins in a variety of CSC systems is summarized in Table 1. Integrin expression itself has been used to enrich for CSCs directly from human patient specimens or xenografted breast,80,81 glioblastoma multiforme (GBM),82 prostate83 and squamous cell carcinoma84,85 tumors. Additionally, integrins have been used to identify cells with CSC properties in animal models of breast86,87 and prostate88 cancer. Aside from functional enrichment, high levels of integrins were linked to a CSC signature and informed poor patient prognosis in glioma82 and breast tumors.89 While it is clear CSC have developed unique integrin signatures to interact with their niches, there are also certain integrins that are reduced or lost, driving the ability of CSCs to proliferate, self-renew, and metastasize. For example, vitronectin via integrin αvβ3 promotes the differentiation of colon and breast CSCs.90 Metastasis can be blocked by integrin α2β1 in a breast cancer animal model91 and integrin αv is a potent inhibitor of metastasis in prostate cancer models both in vitro and in vivo.92,93 These results highlight loss of specific integrin expression is associated with CSCs and a metastasic phenotype. It suggests that integrins serve in many cases to act as anchors, possibly maintaining CSCs as fixed, quiescent entities within their microenvironment preventing replication, differentiation and tumor progression. Importantly, the expression of ECM will be critical to determine as this has been informative in normal neural stem cell niches94,95 and is likely to clarify integrin function in neoplastic niches. Aside from characterizing the signature and function of integrins on CSCs from different tumor types, future studies interrogating the tumor microenvironment are likely to provide a comprehensive landscape of pro- and anti-CSC ECM/integrin relationships that will be informative for prospective CSC enrichment and targeting. Additional integrins are expressed with other cell types within the tumor microenvironment and may overlap, further emphasizing the need to determine the integrin profile in the tumor microenvironment.
Table 1. Integrin signature and function in CSC of various cancers.
| Tumor type | Integrin(s) | Functions |
|---|---|---|
| Breast |
α2β1, α6, β1, β3 |
Used for enrichment from human specimens (β3,80 α681) and mouse models (α686,87), prognostic indicator (α689), suppressor of metastasis in mouse model (α2β191) |
| Colon |
β1, α2β1 |
Expressed at high levels on single CSCs (β1145), regulates differentiation (α2β1146) |
| GBM |
α6 |
Used for enrichment of human specimens, targeting decreases tumorigenic potential (α682) |
| Leukemia |
β2 |
Absent on AML cells, differentiation increases expression (β2147) |
| Prostate |
α2β1, α6, αv |
Used for enrichment of human specimens (α2β183) and mouse models (α688), targeting blocks metastasis (αv92,93) |
| Squamous cell carcinoma | α6, αvβ6 | Used for enrichment of human specimens (a6,84 αvβ685) |
Cadherins in CSCs: Promoting EMT and Invasion
Cadherins, vital to embryogenesis, have also been implicated in tumorigenesis in numerous and diverse cancer types.96 Upon dysregulation of cadherin function in the tumor mass, cells undergo EMT, breaking contacts with interacting tumor and stromal elements. The lack of normal cell-cell interactions frees tumor cells to migrate, proliferate and differentiate abnormally. These cell behaviors results in tumor invasion, metastasis and progression. With regards to CSCs, sphere formation and tumorigenic potential assays have shown P cadherin and E cadherin regulate the CSC state in prostate97 and breast cancer,98,99 namely self-renewal and tumorigenicity. In these contexts, cadherin interaction with integrins or cadherins on neighboring cells of the CSC niche maintain a quiescent state with stemness increased upon loss of these interactions, correlating with accelerated tumorigenic potential and decreased patient prognosis. Taken together these data suggest that similarly to integrins, cadherins function as anchors with loss of CSC interaction with microenvironmental partners allowing for reentry into the cell cycle with subsequent tumor progression. Cadherins are also expressed on other cell types in the niche and characterization studies identifying conserved and unique cell-type specific cadherins will be beneficial to future targeting efforts.
JAMs in CSCs: Facilitating Cell-Cell Communication and Metastasis
The role of JAM-A in stabilizing integrin β1 suggests the possibility that JAM-A directly mediates the interaction of cells in the tumor microenvironment. As metastasis is involved in the transmigration of malignant tumor cells via lymphatic and/or blood vessels, JAM may also be involved in this process. However, there is conflicting evidence about the precise roles of JAM family members in transmigration and limited information as to how CSCs may be involved. Expression of JAM-A correlates with poor prognosis in breast cancer patients.100 Recent studies have shown that knockdown of JAM-A in MCF7 breast cancer cells reduces their adhesion and migration through the activation of Rap1 GTPase and β1-integrin.101 However, another study observed that overexpression of JAM-A in MDA-MB-231 cells inhibited both migration and invasion through collagen gels.102 Furthermore, JAM-A KD enhances the invasiveness of MDA-MB-231 cells as well as T47D cells.102 These findings suggest that JAM-A regulates the transmigration of tumor cells and is involved in mediating ECM-dependent migration. JAM-A is expressed on hematopoietic stem cells (HSCs) where it plays a role in homing and self-renewal.103 Future studies will be required to determine the role of JAMs in CSCs, which is likely to involve both cell-cell and cell-ECM communication with contributions to multiple pro-tumorigenic phenotypes. While JAMs are expressed on endothelial cells and likely other tumor cell types, further interrogation of JAM expression and function will also provide key CSC cross-talk information.
Receptor Tyrosine Phosphatase PTPμ: Specifying an Invasion Signal
PTPμ is abundantly expressed in the vascular endothelium and brain tissue, but downregulation has been observed in GBM104 and prostate cancers.105 In GBM, PTPμ function is decreased by proteolytic cleavage resulting in the release of an extracellular fragment and upon which the inhibitory effect of PTPμ on cell migration is lost.106,107 Overexpression of PTPμ results in blockade of cell replication and migration. Along these lines, CD133+ glioma cells, putative glioma CSCs, have been shown to display high levels of cleaved PTPμ compared with their CD133- non stem tumor cell counterparts. Further, released PTPμ fragments have been shown to influence glioma cell migration and survival in vitro and are thought to promote tumor progression in vivo.109 Despite these insights, the function of PTPμ in CSC biology remains poorly understood, however observed interactions with cadherin, β-catenin and connexin family members is suggestive of a regulatory role. Taken together, it appears that released PTPμ fragments may serve to promote tumorigenesis while intact PTPμ functions in similar fashion to integrins and cadherins and may maintain the CSC population in a quiescent state while PTPμ expressed on endothelial cells and may have a role in angiogenesis and a differential response to cleavage products.
NCAM
The role of NCAM in tumor progression remains unclear as contradictory results have been obtained.109 Why NCAM 120 expression profiles switch to NCAM 140 and 180 during tumorigenesis is also unclear but may reflect a change in function. In colon carcinoma110 and astrocytoma,111 where it acts as a tumor suppressor, NCAM expression is downregulated. Alternatively, increased expression has been observed in neuroblastoma112 and GBM113 with expression correlating with poorer patient prognosis. NCAM expression has been detected on numerous normal stem cell populations. With regards to CSCs conflicting reports abound. Downregulation of NCAM in CSC populations is observed in peripheral neural sheath tumors114 in contrast to reports in GBM where NCAM expression correlates with Olig 2 expression, a well-known GBM stem cell marker.113 Additional studies are required to further address these issues, better define the role of NCAM in microenvironmental regulation and clarify the expression of NCAM in CSCs and other tumor microenvironment cells.
ICAM
ICAM-1, in similar fashion to NCAM, has a checkered history with conflicting reports. In breast cancer,115 ICAM-1 has been associated with improved prognosis. Alternatively, breast cancers have also shown elevated levels of ICAM-1 as compared with surrounding healthy tissue with knockdown correlating with decreased invasive potential.116 Similarly, poorer patient prognosis in melanoma117 and colorectal cancer118,119 is associated with increased ICAM-1 expression levels. It may be that differential levels of soluble ICAM-1 or immune activation in the host may account for these differences. ICAM-1 is considered a marker for mesechymal stem cells, but little data are available for CSCs. Elevated levels of ICAM-1 have been observed in lung cancer CSCs.120 Additional work is required to evaluate the role of ICAM-1 in the tumor microenvironment and specific expression on all cellular components of the niche.
L1CAM
In multiple cancer types, L1CAM appears to promote tumorigenicity and has been shown in colorectal cancer to be protective against apoptosis induced by chemotherapy.121,122 In colorectal cancer, elevated levels of L1CAM have been observed.123 Additionally, in renal cell carcinoma and melanoma, expression of L1CAM correlates with metastatic progression.124,125 In GBM, L1CAM regulates cell motility126 and CSC display elevated levels of L1CAM vs. normal progenitors and silencing of L1CAM resulted in decreased viability, sphere formation and tumorigenic potential.127 Further, L1CAM’s role has been extended to radiation resistance through the control of DNA checkpoint activation.122 Thus, it appears that in contrast to many other adhesion molecules that maintain a quiescent stem population, L1CAM may be integral in the conversion to a malignant phenotype, essential in therapeutic resistance, and may be restricted to CSCs, depending on the tumor type. L1CAM plays a major role in cell migration and this is extensively reviewed by Kiefer et al. in this issue.
Tight Junctions: Joining Together Cells for CSC Maintenance
With regards to CSCs, EMT is associated with the acquisition of stem cell traits leading to cell outgrowth, and tumor progression.128,129 It is unclear what role of tight junction disruption plays in the acquisition of stem cell traits and CSC function. However, a claudin low phenotype has been observed in breast CSCs, suggestive of decreased tight junction formation.130,131 It therefore appears that, like integrins and cadherins, tight junctions serve to maintain the CSC compartment in a quiescent state, with disruption of these contacts resulting in cell migration, replication, and thereby driving tumor progression. Tight junctions are also expressed on other niche cells, although the roles may be different than that in CSCs and may be a reflection of cell-type specific functions.
Gap Junctions: Mediating Cell-Cell Communication in CSCs
Cell-cell communication is another mechanism by which cells are capable of rapidly transferring nutrients and ions between adjacent cells. This may be a driving force in translating single cell events to tumor phenotypes or response to therapies.132 From the perspective of a tumor which contains cellular heterogeneity, how gap junctions regulate CSC communication with one another and other normal and neoplastic cell types remains poorly understood.133 Gap junctions are composed of two hemichannels consisting of six individual connexin (Cx) subunits and among stem cells, Cx43 is one of the most well characterized. Cx43 is highly expressed on neural stem cells,134 regulating proliferation and self-renewal135 as well as migration.136 Cx43 has recently been shown to regulate hematopoietic stem cell interaction with the osteogenic niche.137 However, gap junctions may have different roles depending on the tumor type and specific connexins. For example, Cx43 expression is reduced with increased brain tumor malignancy138 and overexpression in glioma CSCs increases tumor latency.139 Similar results were also observed with elevated Cx43 expression in a model of fibrosarcoma.140 There is evidence for increased connexin expression in CSCs. For example, in a hepatoma model of CSCs, accumulation of Cx32 increased self-renewal.141 These studies provide evidence that connexins may regulate aspects of the CSC phenotype. Further studies in human derived patient CSCs and mouse models will better define their role in driving CSC maintenance. Additionally, it may be possible for different cell types (both normal and neoplastic) to communicate via unique connexins. While the specific connexin(s) were not indicated, gap junction mediated communication between leukemia cells and the stroma in an in vitro model inhibited proliferation and increased therapeutic resistance.142 While there is limited evidence for gap junction specific expression only on CSCs, other niche cells express various Cx subunits and defining the cell-type specific Cx units within the tumor microenvironment and their function is a top priority. Furthermore, functional studies on CSCs and correlating single cell communication to tumor phenotypes will likely transform our view of cancer and drive the development of more effective therapies.
Future Perspectives: Expanding the Network
CSCs are key components of the tumor, driving progression and therapeutic resistance. As they are contained within distinct niches, communication mechanisms within the microenvironment are likely to contribute to many aspects of their phenotype as well as regulate the niche itself. The expression pattern of CSCs themselves may contribute to the composition of the niche and influence the behavior of other niche cells. While data are still accumulating for cell adhesion molecules and direct communication mechanisms, specific growth factors have been shown to originate from CSCs and influence niche cells143 as well as niche cells influencing CSC maintenance by specific mitogens.144 It is likely that ECM ligands and cell-cell interactions will show the same reciprocal relationships and models are likely to emerge in which the CSC have receptors for ligands that are produced by the tumor microenvironment. Furthermore, these microenvironmental components are also likely to influence mode of cell division, ultimately influencing CSC numbers and the overall tumor phenotype.
From what is known, integrins and cadherins regulate stem cell behaviors, namely niche homing, maintenance of the stem cell in the niche, as well as recruitment of stromal cells such as endothelial cells, fibroblasts, and immune cells. A similar function in the CSC niche is likely whereby integrins and cadherins act as tracks for homing to the niche in addition to acting as factors which maintain CSCs. PTPμ may play a role in the conformation of a quiescent phenotype on CSCs once they have entered the stem cell niche along integrin and cadherin tracts. JAM has previously been described in transendothelial cell migration of leukocytes. Additionally, JAM signaling has been shown to increase integrin expression in epithelial cells. It is unclear what role JAM plays in CSC biology as conflicting reports exist. Taken together, JAM may therefore serve to fertilize the microenvironmental soil allowing for CSC entry and retention. NCAM, ICAM and L1CAM function in stromal cell recruitment. NCAM and ICAM display contradictory results with regards to CSC function. L1CAM on the other hand appears to promote CSC mediated tumorigenesis and metastasis. Differences in receptor expression and function may be context or tumor type dependent relying on a milieu of cell receptors and ligands to mediate a cumulative effect on cell recruitment and retention.
Changes extending from the niche to the entire organ during tumor development may also provide cues to CSCs. Integrating this information with respect to how cells at the individual level communicate with one another as well as the microenvironment will be an important step in developing more effective therapeutic strategies. Specifically, defining the cellular and extra-cellular components of the niche, specific receptors on CSCs, and cell adhesion mechanisms present will aid in this overall goal. Future studies will therefore need to better define how tumor cells communicate within their malignant social network.
Acknowledgments
We regret that many important studies related to cell adhesion and cell communication in cancer stem cells were not discussed due to the limited space and scope in this review. We appreciate the insightful comments of Dhurata Bregu and Dr Anita Hjelmeland. We thank Joe Pangrace for illustration assistance. Work in the Lathia lab is supported by the Lerner Research Institute, Voices Against Brain Cancer, the Ohio Cancer Research Associates and a NIH K99/R00 Pathway to Independence Award CA157948.
Footnotes
Previously published online: www.landesbioscience.com/journals/celladhesion/article/21294
References
- 1.Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11. doi: 10.1038/35102167. [DOI] [PubMed] [Google Scholar]
- 2.Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60. doi: 10.1038/nature05236. [DOI] [PubMed] [Google Scholar]
- 3.Magee JA, Pender NP, Abrahams S, Thornton J, Delanty N, Fortune GM. A comparison of propofol and amobarbital for use in the Wada test. Seizure. 2012;21:399–401. doi: 10.1016/j.seizure.2012.02.001. [DOI] [PubMed] [Google Scholar]
- 4.Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8. [PubMed] [Google Scholar]
- 5.Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. doi: 10.1038/nature03128. [DOI] [PubMed] [Google Scholar]
- 6.Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39:193–206. doi: 10.1002/glia.10094. [DOI] [PubMed] [Google Scholar]
- 7.Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100:15178–83. doi: 10.1073/pnas.2036535100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011–21. doi: 10.1158/0008-5472.CAN-04-1364. [DOI] [PubMed] [Google Scholar]
- 9.Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8. doi: 10.1073/pnas.0530291100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328–37. doi: 10.1158/0008-5472.CAN-05-1343. [DOI] [PubMed] [Google Scholar]
- 11.Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–9. doi: 10.1038/nature06489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10. doi: 10.1038/nature05372. [DOI] [PubMed] [Google Scholar]
- 13.Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5. doi: 10.1038/nature05384. [DOI] [PubMed] [Google Scholar]
- 14.Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51. doi: 10.1158/0008-5472.CAN-05-2018. [DOI] [PubMed] [Google Scholar]
- 15.Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem. 2009;284:16705–9. doi: 10.1074/jbc.R900013200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481:85–9. doi: 10.1038/nature10694. [DOI] [PubMed] [Google Scholar]
- 17.Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 2011;8:482–5. doi: 10.1016/j.stem.2011.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN, et al. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun. 2011;406:643–8. doi: 10.1016/j.bbrc.2011.02.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15. doi: 10.1016/j.cell.2008.03.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992–1009. doi: 10.1016/j.cell.2011.11.016. [DOI] [PubMed] [Google Scholar]
- 21.Hu B, Kong LL, Matthews RT, Viapiano MS. The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem. 2008;283:24848–59. doi: 10.1074/jbc.M801433200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res. 2009;7:1756–70. doi: 10.1158/1541-7786.MCR-09-0207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG. EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J Cell Biol. 2001;155:447–58. doi: 10.1083/jcb.200105017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Schneller M, Vuori K, Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J. 1997;16:5600–7. doi: 10.1093/emboj/16.18.5600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882–92. doi: 10.1093/emboj/18.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, et al. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res. 2006;4:915–26. doi: 10.1158/1541-7786.MCR-06-0184. [DOI] [PubMed] [Google Scholar]
- 27.Soung YH, Clifford JL, Chung J. Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression. BMB Rep. 2010;43:311–8. doi: 10.5483/BMBRep.2010.43.5.311. [DOI] [PubMed] [Google Scholar]
- 28.Xu Z, Jin B. A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell Mol Immunol. 2010;7:11–9. doi: 10.1038/cmi.2009.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Crossin KL, Krushel LA. Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Dev Dyn. 2000;218:260–79. doi: 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
- 30.Ensslen SE, Rosdahl JA, Brady-Kalnay SM. The receptor protein tyrosine phosphatase mu, PTPmu, regulates histogenesis of the chick retina. Dev Biol. 2003;264:106–18. doi: 10.1016/j.ydbio.2003.08.009. [DOI] [PubMed] [Google Scholar]
- 31.Fotis L, Agrogiannis G, Vlachos IS, Pantopoulou A, Margoni A, Kostaki M, et al. Intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at the early stages of atherosclerosis in a rat model. In Vivo. 2012;26:243–50. [PubMed] [Google Scholar]
- 32.Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol. 2000;299:551–72. doi: 10.1006/jmbi.2000.3777. [DOI] [PubMed] [Google Scholar]
- 33.Parisini E, Higgins JM, Liu JH, Brenner MB, Wang JH. The crystal structure of human E-cadherin domains 1 and 2, and comparison with other cadherins in the context of adhesion mechanism. J Mol Biol. 2007;373:401–11. doi: 10.1016/j.jmb.2007.08.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Williams EJ, Williams G, Howell FV, Skaper SD, Walsh FS, Doherty P. Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth. J Biol Chem. 2001;276:43879–86. doi: 10.1074/jbc.M105876200. [DOI] [PubMed] [Google Scholar]
- 35.Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G, et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet. 2007;16:1639–47. doi: 10.1093/hmg/ddm113. [DOI] [PubMed] [Google Scholar]
- 36.Chen WS, Antic D, Matis M, Logan CY, Povelones M, Anderson GA, et al. Asymmetric homotypic interactions of the atypical cadherin flamingo mediate intercellular polarity signaling. Cell. 2008;133:1093–105. doi: 10.1016/j.cell.2008.04.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Laprise P, Langlois MJ, Boucher MJ, Jobin C, Rivard N. Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells. J Cell Physiol. 2004;199:32–9. doi: 10.1002/jcp.10432. [DOI] [PubMed] [Google Scholar]
- 38.Kam Y, Quaranta V. Cadherin-bound beta-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between beta-catenin pools. PLoS One. 2009;4:e4580. doi: 10.1371/journal.pone.0004580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.De Santis G, Miotti S, Mazzi M, Canevari S, Tomassetti A. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene. 2009;28:1206–17. doi: 10.1038/onc.2008.470. [DOI] [PubMed] [Google Scholar]
- 40.McCusker C, Cousin H, Neuner R, Alfandari D. Extracellular cleavage of cadherin-11 by ADAM metalloproteases is essential for Xenopus cranial neural crest cell migration. Mol Biol Cell. 2009;20:78–89. doi: 10.1091/mbc.E08-05-0535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.von Schlippe M, Marshall JF, Perry P, Stone M, Zhu AJ, Hart IR. Functional interaction between E-cadherin and alphav-containing integrins in carcinoma cells. J Cell Sci. 2000;113:425–37. doi: 10.1242/jcs.113.3.425. [DOI] [PubMed] [Google Scholar]
- 42.Perrais M, Chen X, Perez-Moreno M, Gumbiner BM. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell. 2007;18:2013–25. doi: 10.1091/mbc.E06-04-0348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Aurrand-Lions M, Johnson-Leger C, Wong C, Du Pasquier L, Imhof BA. Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members. Blood. 2001;98:3699–707. doi: 10.1182/blood.V98.13.3699. [DOI] [PubMed] [Google Scholar]
- 44.Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol. 2007;7:467–77. doi: 10.1038/nri2096. [DOI] [PubMed] [Google Scholar]
- 45.Bradfield PF, Nourshargh S, Aurrand-Lions M, Imhof BA. JAM family and related proteins in leukocyte migration (Vestweber series) Arterioscler Thromb Vasc Biol. 2007;27:2104–12. doi: 10.1161/ATVBAHA.107.147694. [DOI] [PubMed] [Google Scholar]
- 46.Prota AE, Campbell JA, Schelling P, Forrest JC, Watson MJ, Peters TR, et al. Crystal structure of human junctional adhesion molecule 1: implications for reovirus binding. Proc Natl Acad Sci U S A. 2003;100:5366–71. doi: 10.1073/pnas.0937718100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Guglielmi KM, Johnson EM, Stehle T, Dermody TS. Attachment and cell entry of mammalian orthoreovirus. Curr Top Microbiol Immunol. 2006;309:1–38. doi: 10.1007/3-540-30773-7_1. [DOI] [PubMed] [Google Scholar]
- 48.Severson EA, Jiang L, Ivanov AI, Mandell KJ, Nusrat A, Parkos CA. Cis-dimerization mediates function of junctional adhesion molecule A. Mol Biol Cell. 2008;19:1862–72. doi: 10.1091/mbc.E07-09-0869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Kostrewa D, Brockhaus M, D’Arcy A, Dale GE, Nelboeck P, Schmid G, et al. X-ray structure of junctional adhesion molecule: structural basis for homophilic adhesion via a novel dimerization motif. EMBO J. 2001;20:4391–8. doi: 10.1093/emboj/20.16.4391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Liu Y, Nusrat A, Schnell FJ, Reaves TA, Walsh S, Pochet M, et al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J Cell Sci. 2000;113:2363–74. doi: 10.1242/jcs.113.13.2363. [DOI] [PubMed] [Google Scholar]
- 51.Yamamoto T, Harada N, Kano K, Taya S, Canaani E, Matsuura Y, et al. The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells. J Cell Biol. 1997;139:785–95. doi: 10.1083/jcb.139.3.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Ebnet K, Schulz CU, Meyer Zu Brickwedde MK, Pendl GG, Vestweber D. Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. J Biol Chem. 2000;275:27979–88. doi: 10.1074/jbc.M002363200. [DOI] [PubMed] [Google Scholar]
- 53.Severson EA, Lee WY, Capaldo CT, Nusrat A, Parkos CA. Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate beta1 integrin levels, and enhance cell migration. Mol Biol Cell. 2009;20:1916–25. doi: 10.1091/mbc.E08-10-1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Cismasiu VB, Denes SA, Reiländer H, Michel H, Szedlacsek SE. The MAM (meprin/A5-protein/PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase mu. J Biol Chem. 2004;279:26922–31. doi: 10.1074/jbc.M313115200. [DOI] [PubMed] [Google Scholar]
- 55.Oblander SA, Brady-Kalnay SM. Distinct PTPmu-associated signaling molecules differentially regulate neurite outgrowth on E-, N-, and R-cadherin. Mol Cell Neurosci. 2010;44:78–93. doi: 10.1016/j.mcn.2010.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Sui XF, Kiser TD, Hyun SW, Angelini DJ, Del Vecchio RL, Young BA, et al. Receptor protein tyrosine phosphatase micro regulates the paracellular pathway in human lung microvascular endothelia. Am J Pathol. 2005;166:1247–58. doi: 10.1016/S0002-9440(10)62343-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Brady-Kalnay SM, Rimm DL, Tonks NK. Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo. J Cell Biol. 1995;130:977–86. doi: 10.1083/jcb.130.4.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Giepmans BN, Feiken E, Gebbink MF, Moolenaar WH. Association of connexin43 with a receptor protein tyrosine phosphatase. Cell Commun Adhes. 2003;10:201–5. doi: 10.1080/cac.10.4-6.201.205. [DOI] [PubMed] [Google Scholar]
- 59.Soroka V, Kolkova K, Kastrup JS, Diederichs K, Breed J, Kiselyov VV, et al. Structure and interactions of NCAM Ig1-2-3 suggest a novel zipper mechanism for homophilic adhesion. Structure. 2003;11:1291–301. doi: 10.1016/j.str.2003.09.006. [DOI] [PubMed] [Google Scholar]
- 60.Francavilla C, Cattaneo P, Berezin V, Bock E, Ami D, de Marco A, et al. The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. J Cell Biol. 2009;187:1101–16. doi: 10.1083/jcb.200903030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Hansen SM, Berezin V, Bock E. Signaling mechanisms of neurite outgrowth induced by the cell adhesion molecules NCAM and N-cadherin. Cell Mol Life Sci. 2008;65:3809–21. doi: 10.1007/s00018-008-8290-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Liu R, Shi Y, Yang HJ, Wang L, Zhang S, Xia YY, et al. Neural cell adhesion molecule potentiates the growth of murine melanoma via β-catenin signaling by association with fibroblast growth factor receptor and glycogen synthase kinase-3β. J Biol Chem. 2011;286:26127–37. doi: 10.1074/jbc.M111.237297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol. 2001;3:650–7. doi: 10.1038/35083041. [DOI] [PubMed] [Google Scholar]
- 64.Hayflick JS, Kilgannon P, Gallatin WM. The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. Immunol Res. 1998;17:313–27. doi: 10.1007/BF02786454. [DOI] [PubMed] [Google Scholar]
- 65.Mendez MP, Morris SB, Wilcoxen S, Du M, Monroy YK, Remmer H, et al. Disparate mechanisms of sICAM-1 production in the peripheral lung: contrast between alveolar epithelial cells and pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;294:L807–14. doi: 10.1152/ajplung.00398.2007. [DOI] [PubMed] [Google Scholar]
- 66.Pforte A, Schiessler A, Gais P, von Kress S, Beer B, Riethmüller G, et al. Expression of the adhesion molecule ICAM-1 on alveolar macrophages and in serum in extrinsic allergic alveolitis. Respiration. 1993;60:221–6. doi: 10.1159/000196203. [DOI] [PubMed] [Google Scholar]
- 67.Martinelli R, Gegg M, Longbottom R, Adamson P, Turowski P, Greenwood J. ICAM-1-mediated endothelial nitric oxide synthase activation via calcium and AMP-activated protein kinase is required for transendothelial lymphocyte migration. Mol Biol Cell. 2009;20:995–1005. doi: 10.1091/mbc.E08-06-0636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Crook MF, Southgate KM, Newby AC. Both ICAM-1- and VCAM-1-integrin interactions are important in mediating monocyte adhesion to human saphenous vein. J Vasc Res. 2002;39:221–9. doi: 10.1159/000063687. [DOI] [PubMed] [Google Scholar]
- 69.Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis. 2005;22:475–83. doi: 10.1007/s10585-005-3098-x. [DOI] [PubMed] [Google Scholar]
- 70.Boyd JH, Chau EH, Tokunanga C, Bateman RM, Haljan G, Davani EY, et al. Fibrinogen decreases cardiomyocyte contractility through an ICAM-1-dependent mechanism. Crit Care. 2008;12:R2. doi: 10.1186/cc6213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Chen L, Zhou S. “CRASH”ing with the worm: insights into L1CAM functions and mechanisms. Dev Dyn. 2010;239:1490–501. doi: 10.1002/dvdy.22269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Haspel J, Grumet M. The L1CAM extracellular region: a multi-domain protein with modular and cooperative binding modes. Front Biosci. 2003;8:s1210–25. doi: 10.2741/1108. [DOI] [PubMed] [Google Scholar]
- 73.Friedlander DR, Milev P, Karthikeyan L, Margolis RK, Margolis RU, Grumet M. The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J Cell Biol. 1994;125:669–80. doi: 10.1083/jcb.125.3.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Kiefel H, Bondong S, Erbe-Hoffmann N, Hazin J, Riedle S, Wolf J, et al. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene. 2010;29:4766–78. doi: 10.1038/onc.2010.230. [DOI] [PubMed] [Google Scholar]
- 75.Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H, et al. CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat Cell Biol. 2003;5:819–26. doi: 10.1038/ncb1039. [DOI] [PubMed] [Google Scholar]
- 76.González-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008;1778:729–56. doi: 10.1016/j.bbamem.2007.08.018. [DOI] [PubMed] [Google Scholar]
- 77.Ikenouchi J, Matsuda M, Furuse M, Tsukita S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci. 2003;116:1959–67. doi: 10.1242/jcs.00389. [DOI] [PubMed] [Google Scholar]
- 78.Zhong X, Rescorla FJ. Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal. 2012;24:393–401. doi: 10.1016/j.cellsig.2011.10.005. [DOI] [PubMed] [Google Scholar]
- 79.Moh MC, Shen S. The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adh Migr. 2009;3:334–6. doi: 10.4161/cam.3.4.9246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008;68:7711–7. doi: 10.1158/0008-5472.CAN-08-1949. [DOI] [PubMed] [Google Scholar]
- 81.Vassilopoulos A, Wang RH, Petrovas C, Ambrozak D, Koup R, Deng CX. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci. 2008;4:133–42. doi: 10.7150/ijbs.4.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010;6:421–32. doi: 10.1016/j.stem.2010.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007;67:6796–805. doi: 10.1158/0008-5472.CAN-07-0490. [DOI] [PubMed] [Google Scholar]
- 84.Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-β and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A. 2011;108:10544–9. doi: 10.1073/pnas.1107807108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Dang D, Ramos DM. Identification of alphavbeta6-positive stem cells in oral squamous cell carcinoma. Anticancer Res. 2009;29:2043–9. [PubMed] [Google Scholar]
- 86.Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008;68:4674–82. doi: 10.1158/0008-5472.CAN-07-6353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer. 2008;122:298–304. doi: 10.1002/ijc.23103. [DOI] [PubMed] [Google Scholar]
- 88.Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009;69:8555–62. doi: 10.1158/0008-5472.CAN-08-4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res. 2011;13:R118. doi: 10.1186/bcr3061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Hurt EM, Chan K, Serrat MA, Thomas SB, Veenstra TD, Farrar WL. Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells. 2010;28:390–8. doi: 10.1002/stem.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O’Rear LD, Nashabi A, et al. The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest. 2011;121:226–37. doi: 10.1172/JCI42328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol. 2011;179:2559–68. doi: 10.1016/j.ajpath.2011.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, et al. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011;13:516–25. doi: 10.1593/neo.11122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Lathia JD, Patton B, Eckley DM, Magnus T, Mughal MR, Sasaki T, et al. Patterns of laminins and integrins in the embryonic ventricular zone of the CNS. J Comp Neurol. 2007;505:630–43. doi: 10.1002/cne.21520. [DOI] [PubMed] [Google Scholar]
- 95.Kazanis I, Lathia JD, Vadakkan TJ, Raborn E, Wan R, Mughal MR, et al. Quiescence and activation of stem and precursor cell populations in the subependymal zone of the mammalian brain are associated with distinct cellular and extracellular matrix signals. J Neurosci. 2010;30:9771–81. doi: 10.1523/JNEUROSCI.0700-10.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Strumane K, Berx G, Van Roy F. Cadherins in cancer. Handb Exp Pharmacol 2004:69-103. [DOI] [PubMed] [Google Scholar]
- 97.Bae KM, Parker NN, Dai Y, Vieweg J, Siemann DW. E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res. 2011;1:71–84. [PMC free article] [PubMed] [Google Scholar]
- 98.Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001;3:289–93. doi: 10.1186/bcr309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Vieira AF, Ricardo S, Ablett MP, Dionísio MR, Mendes N, Albergaria A, et al. P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer. Stem Cells. 2012;30:854–64. doi: 10.1002/stem.1075. [DOI] [PubMed] [Google Scholar]
- 100.McSherry EA, McGee SF, Jirstrom K, Doyle EM, Brennan DJ, Landberg G, et al. JAM-A expression positively correlates with poor prognosis in breast cancer patients. Int J Cancer. 2009;125:1343–51. doi: 10.1002/ijc.24498. [DOI] [PubMed] [Google Scholar]
- 101.McSherry EA, Brennan K, Hudson L, Hill AD, Hopkins AM. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res. 2011;13:R31. doi: 10.1186/bcr2853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Naik MU, Naik TU, Suckow AT, Duncan MK, Naik UP. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res. 2008;68:2194–203. doi: 10.1158/0008-5472.CAN-07-3057. [DOI] [PubMed] [Google Scholar]
- 103.Sugano Y, Takeuchi M, Hirata A, Matsushita H, Kitamura T, Tanaka M, et al. Junctional adhesion molecule-A, JAM-A, is a novel cell-surface marker for long-term repopulating hematopoietic stem cells. Blood. 2008;111:1167–72. doi: 10.1182/blood-2007-03-081554. [DOI] [PubMed] [Google Scholar]
- 104.Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, Major DL, Zaremba A, et al. PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol. 2009;11:767–78. doi: 10.1215/15228517-2009-019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Hellberg CB, Burden-Gulley SM, Pietz GE, Brady-Kalnay SM. Expression of the receptor protein-tyrosine phosphatase, PTPmu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells. J Biol Chem. 2002;277:11165–73. doi: 10.1074/jbc.M112157200. [DOI] [PubMed] [Google Scholar]
- 106.Burgoyne AM, Phillips-Mason PJ, Burden-Gulley SM, Robinson S, Sloan AE, Miller RH, et al. Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res. 2009;69:6960–8. doi: 10.1158/0008-5472.CAN-09-0863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Burden-Gulley SM, Gates TJ, Burgoyne AM, Cutter JL, Lodowski DT, Robinson S, et al. A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. Neoplasia. 2010;12:305–16. doi: 10.1593/neo.91940. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Kaur H, Burden-Gulley SM, Phillips-Mason PJ, Basilion JP, Sloan AE, Brady-Kalnay SM. Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo. Neuro Oncol. 2012;14:561–73. doi: 10.1093/neuonc/nos066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Zecchini S, Cavallaro U. Neural cell adhesion molecule in cancer: expression and mechanisms. Adv Exp Med Biol. 2010;663:319–33. doi: 10.1007/978-1-4419-1170-4_20. [DOI] [PubMed] [Google Scholar]
- 110.Roesler J, Srivatsan E, Moatamed F, Peters J, Livingston EH. Tumor suppressor activity of neural cell adhesion molecule in colon carcinoma. Am J Surg. 1997;174:251–7. doi: 10.1016/S0002-9610(97)00142-6. [DOI] [PubMed] [Google Scholar]
- 111.Sasaki H, Yoshida K, Ikeda E, Asou H, Inaba M, Otani M, et al. Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer. 1998;82:1921–31. doi: 10.1002/(SICI)1097-0142(19980515)82:10<1921::AID-CNCR16>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- 112.Sjöstrand D, Ibáñez CF. Insights into GFRalpha1 regulation of neural cell adhesion molecule (NCAM) function from structure-function analysis of the NCAM/GFRalpha1 receptor complex. J Biol Chem. 2008;283:13792–8. doi: 10.1074/jbc.M800283200. [DOI] [PubMed] [Google Scholar]
- 113.Amoureux MC, Coulibaly B, Chinot O, Loundou A, Metellus P, Rougon G, et al. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer. 2010;10:91. doi: 10.1186/1471-2407-10-91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, et al. Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS One. 2011;6:e21099. doi: 10.1371/journal.pone.0021099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol. 2011;137:1193–201. doi: 10.1007/s00432-011-0984-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26:943–50. doi: 10.1093/carcin/bgi070. [DOI] [PubMed] [Google Scholar]
- 117.Hamaï A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res. 2008;68:9854–64. doi: 10.1158/0008-5472.CAN-08-0719. [DOI] [PubMed] [Google Scholar]
- 118.Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, et al. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep. 2002;9:511–4. [PubMed] [Google Scholar]
- 119.Tian MM, Sun Y, Li ZW, Wu Y, Zhao AL, Li JY. Polymorphisms of ICAM-1 are associated with gastric cancer risk and prognosis. World J Gastroenterol. 2012;18:368–74. doi: 10.3748/wjg.v18.i4.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 2008;3:e3077. doi: 10.1371/journal.pone.0003077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Sebens Müerköster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007;26:2759–68. doi: 10.1038/sj.onc.1210076. [DOI] [PubMed] [Google Scholar]
- 122.Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011;30:800–13. doi: 10.1038/emboj.2011.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, et al. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol. 2007;20:1183–90. doi: 10.1038/modpathol.3800955. [DOI] [PubMed] [Google Scholar]
- 124.Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G, et al. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002;38:1708–16. doi: 10.1016/S0959-8049(02)00105-3. [DOI] [PubMed] [Google Scholar]
- 125.Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res. 2005;11:1190–7. [PubMed] [Google Scholar]
- 126.Yang M, Li Y, Chilukuri K, Brady OA, Boulos MI, Kappes JC, et al. L1 stimulation of human glioma cell motility correlates with FAK activation. J Neurooncol. 2011;105:27–44. doi: 10.1007/s11060-011-0557-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68:6043–8. doi: 10.1158/0008-5472.CAN-08-1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51. doi: 10.1038/onc.2010.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582–9. doi: 10.1038/embor.2008.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68. doi: 10.1186/bcr2635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Turksen K. Claudins and cancer stem cells. Stem Cell Rev. 2011;7:797–8. doi: 10.1007/s12015-011-9267-1. [DOI] [PubMed] [Google Scholar]
- 132.Trosko JE. The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed Pharmacother. 2005;59(Suppl 2):S326–31. doi: 10.1016/S0753-3322(05)80065-4. [DOI] [PubMed] [Google Scholar]
- 133.Trosko JE, Chang CC, Upham BL, Tai MH. Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication. Ann N Y Acad Sci. 2004;1028:192–201. doi: 10.1196/annals.1322.023. [DOI] [PubMed] [Google Scholar]
- 134.Cai J, Cheng A, Luo Y, Lu C, Mattson MP, Rao MS, et al. Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem. 2004;88:212–26. doi: 10.1046/j.1471-4159.2003.02184.x. [DOI] [PubMed] [Google Scholar]
- 135.Cheng A, Tang H, Cai J, Zhu M, Zhang X, Rao M, et al. Gap junctional communication is required to maintain mouse cortical neural progenitor cells in a proliferative state. Dev Biol. 2004;272:203–16. doi: 10.1016/j.ydbio.2004.04.031. [DOI] [PubMed] [Google Scholar]
- 136.Elias LA, Wang DD, Kriegstein AR. Gap junction adhesion is necessary for radial migration in the neocortex. Nature. 2007;448:901–7. doi: 10.1038/nature06063. [DOI] [PubMed] [Google Scholar]
- 137.Gonzalez-Nieto D, Li L, Kohler A, Ghiaur G, Ishikawa E, Sengupta A, et al. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood. 2012;119:5144–54. doi: 10.1182/blood-2011-07-368506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Soroceanu L, Manning TJ, Jr., Sontheimer H. Reduced expression of connexin-43 and functional gap junction coupling in human gliomas. Glia. 2001;33:107–17. doi: 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
- 139.Yu SC, Xiao HL, Jiang XF, Wang QL, Li Y, Yang XJ, et al. Connexin 43 reverses malignant phenotypes of glioma stem cells by modulating E-cadherin. Stem Cells. 2012;30:108–20. doi: 10.1002/stem.1685. [DOI] [PubMed] [Google Scholar]
- 140.King TJ, Fukushima LH, Yasui Y, Lampe PD, Bertram JS. Inducible expression of the gap junction protein connexin43 decreases the neoplastic potential of HT-1080 human fibrosarcoma cells in vitro and in vivo. Mol Carcinog. 2002;35:29–41. doi: 10.1002/mc.10071. [DOI] [PubMed] [Google Scholar]
- 141.Kawasaki Y, Omori Y, Li Q, Nishikawa Y, Yoshioka T, Yoshida M, et al. Cytoplasmic accumulation of connexin32 expands cancer stem cell population in human HuH7 hepatoma cells by enhancing its self-renewal. Int J Cancer. 2011;128:51–62. doi: 10.1002/ijc.25308. [DOI] [PubMed] [Google Scholar]
- 142.Paraguassú-Braga FH, Borojevic R, Bouzas LF, Barcinski MA, Bonomo A. Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell communication. Cell Death Differ. 2003;10:1101–8. doi: 10.1038/sj.cdd.4401279. [DOI] [PubMed] [Google Scholar]
- 143.Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66:7843–8. doi: 10.1158/0008-5472.CAN-06-1010. [DOI] [PubMed] [Google Scholar]
- 144.Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009;27:2393–404. doi: 10.1002/stem.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A. 2008;105:13427–32. doi: 10.1073/pnas.0805706105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 146.Kirkland SC, Ying H. Alpha2beta1 integrin regulates lineage commitment in multipotent human colorectal cancer cells. J Biol Chem. 2008;283:27612–9. doi: 10.1074/jbc.M802932200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147.Wu JJ, Cantor A, Moscinski LC. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res. 2007;31:49–57. doi: 10.1016/j.leukres.2006.04.012. [DOI] [PubMed] [Google Scholar]

